Prostate Cancer - Results from #28280

CURy 2011 - Abiraterone acetate in castration-resistant prostate cancer - Slide Presentation April 18, 2011

Radical prostatectomy versus external-beam radiotherapy for localized prostate cancer: Long-term effect on biochemical control-in search of the optimal treatment - Abstract April 15, 2011

Salvage lymphadenectomy in postprostatectomy patients with prostate-specific antigen recurrence - Abstract April 15, 2011

The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation - Abstract April 15, 2011

The effect of demographic and clinical factors on the relationship between BMI and PSA levels - Abstract April 15, 2011

A pilot study of endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging changes with dutasteride in patients with low risk prostate cancer - Abstract April 15, 2011

Constitutional risk factors in prostate cancer - Abstract April 15, 2011

Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: Tumor detection and assessment of aggressiveness - Abstract April 15, 2011

Penile implant utilization following treatment for prostate cancer: Analysis of the SEER-Medicare database - Abstract April 14, 2011

Estrogen-initiated transformation of prostate epithelium derived from normal human prostate stem-progenitor cells - Abstract April 14, 2011

Robotic radical prostatectomy: A critical analysis of the impact on cancer control - Abstract April 14, 2011

Biochemical recurrence after radical prostatectomy with or without pelvic lymphadenectomy in Korean men with high-risk prostate cancer - Abstract April 14, 2011

Antioxidant effects of lycopene in African American men with prostate cancer or benign prostate hyperplasia: A randomized controlled trial - Abstract April 14, 2011

Castration-resistant prostate cancer: Targeted therapies - Abstract April 14, 2011

Robotic high-intensity focused ultrasound for prostate cancer: What have we learned in 15 years of clinical use? - Abstract April 14, 2011

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: Results of a 2-year follow-up study - Abstract April 13, 2011

The patient after radical prostatectomy : Complexity and efficiency of a urological rehabilitation program - Abstract April 13, 2011

Durable remission of leptomeningeal metastases from hormone-responsive prostate cancer - Abstract April 13, 2011

Association of serum α-tocopherol with sex steroid hormones and interactions with smoking: Implications for prostate cancer risk - Abstract April 13, 2011

Current perspectives on Gleason grading of prostate cancer - Abstract April 13, 2011

Page 1415 of 1438